Dupixent 300 MG/2 ML syringe 2ML
Ended Awarded
- Contract number
- SPE2DR26F8YJS
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,234
Award facts
- Contract value 100% obligated
- $12,234.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,234.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent (dupilumab) 300 mg/2 mL syringes on October 23, 2025, with an ultimate completion date of October 24, 2025. This is a non-set-aside competitive award for pharmaceutical supply to support federal medical procurement needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a vast range of medications and medical supplies to military healthcare programs worldwide.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical vendor that supplies brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract portfolio demonstrates extensive experience fulfilling diverse medical supply requirements through competitively awarded delivery orders with firm fixed pricing. Dupixent is a biologic immunosuppressant used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis, and this procurement supports the Defense Logistics Agency's medical supply chain for military and veteran healthcare needs.
Quick answers
Who was awarded contract SPE2DR26F8YJS?
SPE2DR26F8YJS was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 23, 2025.
How much is contract SPE2DR26F8YJS worth?
The government has obligated $12,234 on SPE2DR26F8YJS.
Is contract SPE2DR26F8YJS an order under another contract?
Yes. SPE2DR26F8YJS is a delivery order under SPE2DR25D1017, an indefinite delivery contract.
Was contract SPE2DR26F8YJS competed?
The extent of competition for SPE2DR26F8YJS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award